Standard

Bispecific antibodies: Design, therapy, perspectives. / Sedykh, Sergey E.; Prinz, Victor V.; Buneva, Valentina N. et al.

In: Drug Design, Development and Therapy, Vol. 12, 22.01.2018, p. 195-208.

Research output: Contribution to journal › Review article › peer-review

Harvard

Sedykh, SE, Prinz, VV, Buneva, VN & Nevinsky, GA 2018, 'Bispecific antibodies: Design, therapy, perspectives', Drug Design, Development and Therapy, vol. 12, pp. 195-208. https://doi.org/10.2147/DDDT.S151282

APA

Sedykh, S. E., Prinz, V. V., Buneva, V. N., & Nevinsky, G. A. (2018). Bispecific antibodies: Design, therapy, perspectives. Drug Design, Development and Therapy, 12, 195-208. https://doi.org/10.2147/DDDT.S151282

Vancouver

Sedykh SE, Prinz VV, Buneva VN, Nevinsky GA. Bispecific antibodies: Design, therapy, perspectives. Drug Design, Development and Therapy. 2018 Jan 22;12:195-208. doi: 10.2147/DDDT.S151282

Author

Sedykh, Sergey E. ; Prinz, Victor V. ; Buneva, Valentina N. et al. / Bispecific antibodies: Design, therapy, perspectives. In: Drug Design, Development and Therapy. 2018 ; Vol. 12. pp. 195-208.

BibTeX

@article{ab456942f9844a7d8d5766127dbd28a4,
title = "Bispecific antibodies: Design, therapy, perspectives",
abstract = "Antibodies (Abs) containing two different antigen-binding sites in one molecule are called bispecific. Bispecific Abs (BsAbs) were first described in the 1960s, the first monoclonal BsAbs were generated in the 1980s by hybridoma technology, and the first article describing the therapeutic use of BsAbs was published in 1992, but the number of papers devoted to BsAbs has increased significantly in the last 10 years. Particular interest in BsAbs is due to their therapeutic use. In the last decade, two BsAbs – catumaxomab in 2009 and blinatumomab in 2014, were approved for therapeutic use. Papers published in recent years have been devoted to various methods of BsAb generation by genetic engineering and chemical conjugation, and describe preclinical and clinical trials of these drugs in a variety of diseases. This review considers diverse BsAb-production methods, describes features of therapeutic BsAbs approved for medical use, and summarizes the prospects of practical application of promising new BsAbs.",
keywords = "Bispecific antibodies, Monoclonal antibodies, Therapeutic antibodies",
author = "Sedykh, {Sergey E.} and Prinz, {Victor V.} and Buneva, {Valentina N.} and Nevinsky, {Georgy A.}",
note = "This study was funded by the Russian Foundation for Basic Research, according to the research projects 16-34-60066-mol_a_dk, 16-15-10103-a, and 16-04-00603-a, and with a grant from the Ministry of Education and Science (MK-410.2017.4).",
year = "2018",
month = jan,
day = "22",
doi = "10.2147/DDDT.S151282",
language = "English",
volume = "12",
pages = "195--208",
journal = "Drug Design, Development and Therapy",
issn = "1177-8881",
publisher = "Dove Medical Press Ltd.",

}

RIS

TY - JOUR

T1 - Bispecific antibodies: Design, therapy, perspectives

AU - Sedykh, Sergey E.

AU - Prinz, Victor V.

AU - Buneva, Valentina N.

AU - Nevinsky, Georgy A.

N1 - This study was funded by the Russian Foundation for Basic Research, according to the research projects 16-34-60066-mol_a_dk, 16-15-10103-a, and 16-04-00603-a, and with a grant from the Ministry of Education and Science (MK-410.2017.4).

PY - 2018/1/22

Y1 - 2018/1/22

N2 - Antibodies (Abs) containing two different antigen-binding sites in one molecule are called bispecific. Bispecific Abs (BsAbs) were first described in the 1960s, the first monoclonal BsAbs were generated in the 1980s by hybridoma technology, and the first article describing the therapeutic use of BsAbs was published in 1992, but the number of papers devoted to BsAbs has increased significantly in the last 10 years. Particular interest in BsAbs is due to their therapeutic use. In the last decade, two BsAbs – catumaxomab in 2009 and blinatumomab in 2014, were approved for therapeutic use. Papers published in recent years have been devoted to various methods of BsAb generation by genetic engineering and chemical conjugation, and describe preclinical and clinical trials of these drugs in a variety of diseases. This review considers diverse BsAb-production methods, describes features of therapeutic BsAbs approved for medical use, and summarizes the prospects of practical application of promising new BsAbs.

AB - Antibodies (Abs) containing two different antigen-binding sites in one molecule are called bispecific. Bispecific Abs (BsAbs) were first described in the 1960s, the first monoclonal BsAbs were generated in the 1980s by hybridoma technology, and the first article describing the therapeutic use of BsAbs was published in 1992, but the number of papers devoted to BsAbs has increased significantly in the last 10 years. Particular interest in BsAbs is due to their therapeutic use. In the last decade, two BsAbs – catumaxomab in 2009 and blinatumomab in 2014, were approved for therapeutic use. Papers published in recent years have been devoted to various methods of BsAb generation by genetic engineering and chemical conjugation, and describe preclinical and clinical trials of these drugs in a variety of diseases. This review considers diverse BsAb-production methods, describes features of therapeutic BsAbs approved for medical use, and summarizes the prospects of practical application of promising new BsAbs.

KW - Bispecific antibodies

KW - Monoclonal antibodies

KW - Therapeutic antibodies

UR - http://www.scopus.com/inward/record.url?scp=85041494748&partnerID=8YFLogxK

UR - https://elibrary.ru/item.asp?id=35483818

U2 - 10.2147/DDDT.S151282

DO - 10.2147/DDDT.S151282

M3 - Review article

C2 - 29403265

AN - SCOPUS:85041494748

VL - 12

SP - 195

EP - 208

JO - Drug Design, Development and Therapy

JF - Drug Design, Development and Therapy

SN - 1177-8881

ER -

ID: 10352457